Based on pre-clinical and clinical data as well as our preliminary observations, this intervention should be especially considered in, but not limited to, salvage therapies for refractory ALL with TCF3-HLF fusion or KMT2A rearrangements and any refractory AML. This evidence concerns the gene TCF3 and acute myeloid leukemia.